- Poland
- /
- Healthtech
- /
- WSE:MDA
MedApp Reports First Quarter 2025 Earnings
MedApp (WSE:MDA) First Quarter 2025 Results
Key Financial Results
- Revenue: zł1.29m (up 16% from 1Q 2024).
- Net loss: zł479.0k (loss narrowed by 47% from 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
MedApp shares are down 2.4% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 3 warning signs for MedApp you should be aware of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:MDA
MedApp
Engages in the development of solutions to support imaging diagnostics and digital medicine in Poland, rest of the European Union, and internationally.
Excellent balance sheet with slight risk.
Market Insights
Weekly Picks

The "Physical AI" Monopoly – A New Industrial Revolution
Czechoslovak Group - is it really so hot?

The Compound Effect: From Acquisition to Integration
Recently Updated Narratives

Norwegian Air Shuttle's revenue will grow by 73.56% and profitability will soar

Investment Thesis: Olvi Oyj (OLVAS)

UnitedHealth Group's Future Revenue Grows by 3.59%: What Will It Mean?
Popular Narratives

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks
